Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND
No-Receipt date
2022-00810 - 02/03/2022
No-Filing date
20220400492 - 02/03/2022
No-Granting date
3109835 - 11/03/2022
No-EPO application date
18724754.9 - 30/04/2018
No-EPO granting date
3601283 - 29/12/2021
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
3/2022 - 18/04/2022
Expiration date
01/05/2038
Kind of title
Validation of European Patent
Legal status
NOT VALID
Priorities
US201762492574 P01/05/2017/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61K 31/437
A61P 11/00
A61P 17/00
A61P 27/02
C07D 471/04
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
1395769
THERAVANCE BIOPHARMA R&D IP, LLC
901 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
3593792
FATHEREE, PAUL R.
3593793
JIANG, LAN
3593794
MCKINNELL, ROBERT MURRAY
3593795
THALLADI, VENKAT R.
3593796
ZHANG, HAO
3593797
DABROS, MARTA
3593798
NZEREM, JERRY
3593799
BENJAMIN, NOAH
3593800
KLEINSCHEK, MELANIE A.
3593801
CRATER, GLENN D.
Representatives
Code
Firstname
Surname
Address
Town
Zip
3089
NIKOLAOS
LYMPERIS "DIKIGORIKI ETAIREIA VAGIANOU KOSTOPOULOU LYMPERI"
STOURNARI 37
ATHINA (ATTIKIS)
10682
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
7915
NIKOLAOS
LYMPERIS
STOURNARI 37
ATHINA (ATTIKIS)
10682
GREECE
Owners History
Title Instruments
Date
Operation
Descreption
11/4/2024 12:00:00 AM
Έκπτωση Κύριων Τίτλων (79602)
ΕΚΠΤΩΣΕΙΣ 10/2024 Αρ. Πρωτ. ΓΔ 3111/04.11.2024
Payments history
6 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).